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ABSTRACT
The dopamine transporter (DAT) is an integral membrane protein that reuptakes
dopamine (DA) from the extracellular space into the presynaptic neuron. DAT regulates
dopaminergic neurotransmission as it maintains homeostatic synaptic DA levels in the
brain. Psychostimulants such as cocaine disrupt DA homeostasis as it binds to DAT and
prevents reuptake of DA. Excess DA in the synapse leads to prolonged dopaminergic
neurotransmission, which is associated with cocaine related euphoria often leading to
addiction.
The DAT consists of 12 transmembrane domains (TMs) with N- and C-termini
facing the cytoplasm. TMs 1, 3, 6, and 8 make up the core of the protein and the residues
from these domains are involved in binding substrates and inhibitors. Although the effect
of cocaine binding to DAT is known, the mechanism of DAT-cocaine interaction at the
molecular level is still unknown. Therefore, to elucidate how cocaine binds to the DAT
and how it is positioned in the binding pocket, we mapped the attachment site of the
irreversible binding cocaine analogs, [125I]MFZ 2-24, [125I]RTI 82, and [125I]JHC 2-48.
These compounds share a similar cocaine-based core structure, but have analog specific
photo activatable side chains that extend from different regions of the cocaine core
structure. Upon ultraviolet light activation, the photo activatable phenyl N3 (azido) group
forms phenyl nitrene that becomes covalently attached to a residue on the protein, hence
irreversible binding cocaine analogs.
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Previous studies narrowed the [125I]RTI 82 adduction site to the region
surrounding TM6, between Ile291 and Arg344 on human DAT and between Met290 and
Lys336 on rat DAT. The [125I]MFZ 2-24 attachment site was localized between residues
Ile67 and Leu80 in TM1. To identify the specific amino acid attachment site of these
analogs we created several methionine substitution mutants across TMs 1 and 6. This
resulted in generation of custom cyanogen bromide (CNBr) cleavage sites. The results
from peptide maps of photoaffinity labeled mutants proteolyzed with CNBr narrowed the
adduction of [125I]MFZ 2-24 to Asp79 or Leu80 in TM1 and the adduction of [125I]RTI
82 to Phe320 in TM6. Trypsin and CNBr proteolysis of [125I]JHC 2-48 labeled rat DAT
indicated a ligand attachment site C-terminal to TM6. Incorporation of three structural
analogs to three distinct TM domains demonstrates that the appended azido groups on
these analogs identify different faces of the ligand binding pocket. Thus, allowing for
triangulation of cocaine orientation in its binding site via computational modeling.
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CHAPTER I

INTRODUCTION
	
  
	
  

Dopamine: Discovery, Synthesis and Degradation
Dopamine (DA) was discovered as a neurotransmitter in 1957 by Dr. Arvid

Carlsson (1). Prior to that discovery, DA was thought just to function as a precursor to
norepinephrine (1–3). Dopamine governs several physiological roles such as movement,
mood, and reward/pleasure. It is considered to be both an inhibitory and an excitatory
neurotransmitter depending on synaptic context.
Dopaminergic neurons synthesize DA from tyrosine. Tyrosine is transported into
the dopaminergic neurons via amino acid transporters. Once in the neuron, it is converted
to DA in a two-step enzymatic process. 1) Cytosolic tyrosine hydroxylase (TH) along
with the cofactors oxygen, iron, and tetrahydrobiopterin hydroxylates tyrosine to generate
L-3, 4-dihydroxyphenylalanine (L-DOPA), then 2) L-DOPA is decarboxylated to
produce dopamine by aromatic L-amino acid decarboxylase (AADC) along with the
cofactor pyridoxal phosphate (Figure 1A). The first biosynthesis step catalyzed by TH is
the rate limiting step (4). Since DA is the starting compound to generate other
neurotransmitters such as norepinephrine and epinephrine, DA synthesis regulates
synthesis of other catecholamines.
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Figure 1: Biosynthesis and biodegradation of dopamine. Dopamine is synthesized
from tyrosine with L-3, 4-dihydroxyphenylalanine (L-DOPA) as an intermediate.
Enzymes involved are shown below the arrows. The first catalytic reaction involving
tyrosine hydroxylase (TH) is the rate limiting reaction. B) Biodegradation of
dopamine. Homovanillic acid (HVA) is the most common product of dopamine
degradation in humans.
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Once synthesized in the body of the neuron, DA molecules are transported toward the
nerve terminal and packaged into synaptic vesicles via the vesicular monoamine
transporter 2 (VMAT-2), this act helps to prevent oxidative stress in the cytosol (5). The
concentration of the neurotransmitter inside the vesicle is 0.1 M, which is 10-100 times
higher than in cytosol (4). In addition to the terminal regions, DA synthesis and release
also occurs in the dentrites (4).
Upon the arrival of action potential, vesicles storing DA fuse with the membrane
and release neurotransmitters into the synapse via calcium (Ca+2)-mediated exocytosis.
Once in the synapse, DA molecules bind to the pre and post-synaptic dopamine receptors
and activate them. This leads to propagation of dopaminergic neurotransmission.
Neurotransmission is terminated when excess DA is removed from the synapse. Excess
DA in the synapse either diffuses away or is taken back into the pre-synaptic neuron or
into the surrounding cells. Once DA is in the presynaptic neuron, it either gets degraded
(Figure 1B) or gets repackaged into storage vesicles and awaits the arrival of another
nerve stimulation. The amount of dopamine released into the synapse is controlled by the
pattern and rate of neuronal firing (6). A schematic diagram of a dopaminergic synapse is
depicted in Figure 2.

	
  
	
  

The Dopaminergic Pathways in the Mammalian Central Nervous System
Soon after the identification of DA as a neurotransmitter, researchers focused to

identify the neurons that produce DA. Dopaminergic neurons in vivo were identified by
fluorescence histochemistry. This technique causes DA to fluoresce when it is combined
with a treatment substance, thus lightening up the neurons containing DA (7). Several
studies also identified dopaminergic neurons by selecting neurons that contain enzymes
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Figure 2: Schematic	
  diagram	
  of	
  a	
  dopaminergic	
  synapse.	
  Once dopamine molecules
(orange dots) are synthesized they are packaged into synaptic vesicles (blue circles)
via the vesicular monoamine transporter 2 (VMAT-2; purple cylinders). Upon neuron
stimulation the synaptic vesicles dock at the plasma membrane and release dopamine
into the synapse via Ca+2-mediated exocytosis. Dopamine binds to the post-synaptic
receptors (teal cylinders) and initiates dopaminergic neurotransmission (yellow
lightening bolts). Dopamine also modulates the autoreceptors (teal cylinders) in the
presynaptic neurons. Dopaminergic neurotransmission is terminated when dopamine is
removed from the synapse via the dopamine transporter (red trapezoids). Once
dopamine is inside the cell it is either repackaged into synaptic vesicles (blue circle) or
gets degraded.
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needed for DA biosynthesis (8–10). For example, TH positive neurons were identified as
DA-neurons, however, later it was discovered that not all TH positive cells produce DA
and therefore are not dopaminergic neurons (11).
Although DA is one of the most abundant catecholamines, dopaminergic neurons
account for less than 1% of the total neurons in the body. These neurons are localized in
several regions including the retina, the olfactory bulb, mesencephalon, medulla
oblongata, and hypothalamus. There are four main dopaminergic pathways in the brain
(Figure 3). 1) Nigrostriatal pathway, which extends from the substantia nigra (SN) to
striatum in the basal ganglia. These neurons are involved in motor control and movement.
2) Mesolimbic pathway, which projects from the ventral tegmental area (VTA) to the
nucleus accumbens. These neurons are involved in the reward and pleasure pathways. 3)
Mesocortical pathway, which projects from the VTA to the cortex. These neurons govern
motivation, emotion, and attention. 4) Tuberinfundibular pathway, which extends from
the hypothalamus to the posterior pituitary. These neurons are involved in inhibition of
prolactin secretion. The majority of the dopaminergic neurons are populated in the SN
region of the basal ganglia.
Several diseases or disorders occur from dysregulation of these neurons.
Dyskinesia and Parkinson’s disease result from dysregulation of Nigrostriatal pathway.
Schizophrenia and addiction result from dysregulation of Mesolimbic pathway. Attention
deficit hyperactivity disorder and depression result from dysregulation of Mesocortical
pathway.
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Figure 3: Dopaminergic pathways in the human brain. The four major pathways are:
Nigrostriatal (red), Mesocortical (blue), Mesolimbic (green), and Tuberinfundibular
(pink) pathways.
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The Dopamine Transporter

	
  
	
  
Neurotransmitter

sodium

symporters

(NSS)

use

sodium

and

chloride

electrochemical gradients to drive the reuptake of neurotransmitters such as dopamine,
serotonin, and norepinephrine or the reuptake of amino acids such as gammaaminobutyric acid (GABA) and glycine. These transporters belong to the subfamily
solute carrier family 6 (SLC6). In the early 1990s a group of investigators cloned the rat
GABA transporter type 1 (rGAT1) encoding gene (12) and hydropathy analysis of GAT
and other NSS proteins provided the first structural evidence that these proteins have 12
transmembrane domains with intracellular N- and C-termini (12–14).
The dopamine transporter (DAT) regulates dopaminergic homeostasis by reuptaking dopamine from the synapse back into the presynaptic neurons. DAT from
several species such as rat, human, mouse, monkey, Drosophila melanogaster, and
Caenorhabditis elegans have been cloned. Human (h) DAT and rat (r) DAT sequences
have an overall sequence identity of 92%. hDAT and rDAT are composed of 620 and 619
amino acids, respectively, with hDAT containing an extra glycine at position 199 (15).
The transmembrane domains are highly conserved between mammalian DAT in regards
to the intracellular (IL), extracellular (EL), N- and C-termini. EL2, which connects TM
domains 3 and 4, is the largest loop and contains glycosylation sites. Additionally, there
are four zinc coordinating sites at positions H193 (EL2), D206 (EL2) H375 (EL4) and
E396 (EL4) on hDAT (16, 17). Zinc stabilizes the outward facing conformation of DAT
and acts as DA uptake inhibitor.
DAT is regulated by several post-translational modifications such as
phosphorylation,

	
  

palmitoylation,

ubiquitylation,

10

and

glycosylation

(Figure

4).

Phosphorylation is a reversible modification in which a phosphate (PO43-) group is added
to serine, threonine, or tyrosine by a protein kinase. Some key roles of phosphorylation
are protein trafficking, protein-protein interaction, and substrate efflux. Threonine 53 and
a cluster of serine residues that includes Ser7 in the N- terminal tail on rDAT are a few of
the phosphorylation sites (18–22). Proteins are dephosphorylated by protein phosphatases.
Another reversible post-translational modification is palmitoylation. It is also a reversible
modification where a palmitate group, a 16-chain fatty acid, is added to cysteine residues
via a thioester linkage by palmitoyl acyltransferases. This process is reversed by
palmitoyl protein thioesterases. Palmitoylation regulates several protein functions
including trafficking, stability, and sorting of neuronal proteins (23–25). In regards to
DAT, the exact role of palmitoylation is not completely understood. rDAT is
palmitoylated at cysteine 580, which is located near the base of TM 12. Other
palmitoylation sites are likely to exist but have not been identified yet. Palmitoylation and
phosphorylation appear to regulate DAT reciprocally, as palmitoylation helps to stabilize
protein on the membrane, and phosphorylation is associated with DAT internalization
(26).
Ubiquitylation is a post-translational modification where a ubiquitin group is
added to a lysine residue. Protein ubiquitylation governs its interaction with other
proteins, its cellular localization, and degradation. In DAT, lysine residues present in the
N-terminal tail are the targets for ubiquitylation, which mediates PKC–dependent
endocytosis (27, 28). Another post-translation modification DAT undergoes is
glycosylation. There are several experimentally determined N-glycosylation sites in EL2
of DAT as denoted by the sequence N-X-S/T. Glycosylation of DAT has been linked to
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Figure 4: Schematic diagram of rDAT. The structure contains 12 transmembrane
domains with N- and C-termini localized intracellular. Residues in blue represent
the residues present in transmembrane domains while residues in tan represent intraor extracellular residues. Phosphorylation sites discovered thus far are denoted by
red circles with “P.” Ubiquitylation site are denoted by yellow circles in “Ub.”
Glycosylation sites and disulfide bond present in EL2 are denoted by green and
purple colors, respectively. Palmitoylation site is denoted by orange circle with
“Pal.”
	
  

	
  

12

A E Y F
P A T
E R
G T F G V L
T
D
H
L N
N
L
S
H
A
Q
H
S
A
R
D
G
S P N
C S
N
D G P G
I
Y L S
T
R A
I F L
W
D
I
V
A
I
D G
T N N C H I W
I Y
D V R
D
D
M
P L D
P E
P I
A
L
A
F
M
I A
Y I F
N V
G
H
T
G
A
P
K
Y
T
L
P
G Y
D
Q
P
F
P
R
S
H P
L
W
S L
F S
A
L
S
P
Y
I
P
M
V
G
G
C
R
A
G
F
Y
F T
F
G
K N
W
A N
T
A E S
H Y L
G
T V
L L
C Y
A A
A
W R
G V R
F L
T N
V
A G
A
Q
I
L
V
W
D
F
S
S
V
W
L
Y
G W L
A
F
C
H F
F F
L
I
V V
T
L L
V
F
L
D
V
I
F P R
A
V
L
A
L
C
V
A
A A T
I A I
A
Y P
F
S
V I N
L M
L
V
G
T
L
L
G
L
V W
V
S
Y L
L
T S
L
T S
L
Y
L
T
N
V Q
V
S
F
F
V
F
L
A
L
V
S
F
T
F
I L
I
F C
M
V M
F C
I G
G
D L V
P Y M
T S L
F G
L A V
L V L
P
D
A I
M V A
L S G
Y V F
S V
V L
A S
G
F A
N S
A T
Y
P I
G I
L K
I
G V
L
I S
P M L
S F L
G M
S I
I G
I T
T
E
Y
L
F
G
W
T
V
W
A I
A T
G
F
M
I
T
C
V
S
L F E
K W
I
E
G
V
L V I
L
M Y E
Y K
T V
R W L
V A
A I
V S
G K
F L
H R
F
G
Y L
G F
D
F A
W
A L L
T I
V K T S
Pal
I D
S L C
G V K
Y R
L G
R
S
N
K K
Q G
P
F
L
V
C
F
V
D
G S
H
S
E
S
R N
P
L
Y
N
F
P
L
F Q
W
E
Y
K LR E
R
N
G
C
V Q
A Y
N K
T
G
Q
A I
F T
Q
I
F S
E
T
A
D
G
D I
R
P
A G V WK
K Q M T
E
E
P
A Q
E
K
P V
T
H D
Q
E G R D V L Q
V
P
R
Q
S N T L
P N
F
I L T
T
Q
L
R
V
H
L L L W
Q N G
V K E
M
I L
L
P
S
K
E
Ub
P
S
Ub
C K
V
V S
S M P G
E
A V V S
S E K A P
R P
G V A N
D G L
S S
G

J. D. Foster and R. A. Vaughan 2013

	
  

13

surface expression which allows DAT to function properly (29–31). Additionally, proper
DAT function is also facilitated by proper folding of the protein, which is facilitated by
the disulfide bond present in the EL2 between cysteines 180 and 189 (32, 33).
In addition to the post-translational modifications, DAT is also regulated by
several proteins that interact with DAT at the N-terminal or C-terminal tails. Syntaxin 1A,
protein kinase C (PKC), and protein phosphatase 2A (PP2Ac) interact with DAT via the
N-terminus while α-synuclein, calcium-dependent calmodulin kinase II (CaMKII) and
protein interacting with C kinase-1 (PICK1) interact via the C-terminus (34–36).
DAT: Tertiary Structure
	
  
	
  
In 2005, the Gouaux laboratory crystalized the leucine transporter from the
bacterium Aquifex aeolicus (LeuTAa) with the substrate leucine and 2 sodium ions. This
provided critical insights into the tertiary structure of homologous transporters such as
DAT. LeuTAa was shown to have a 5+5 helical architecture where TMs 1-5 and 6-10
form helical bundles that are antiparallel, resulting in a pseudo-two-fold axis of symmetry.
TMs 1 and 6 contain an unwound region in the middle of the transmembrane that
represents non-continuous helices. These two domains along with 3 and 8 form the core
of the protein, which contains the substrate-binding site half way into the lipid bilayer
(Figure 5). Although the overall sequence identity between LeuT and DAT is only 20%,
the residues in the core of the protein surrounding the substrate binding sites are highly
conserved with 67% sequence identity, suggesting not only the importance of these
residues but also a similar mechanism of transport. TMs 11 and 12 reside on the
periphery of the bundle domains. Conserved amino acids throughout the TMs are
indicative of their importance in structure-function of the proteins (37, 38).
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Figure 5: Schematic 2D representation of DAT based upon LeuTAa crystal structure.
Transmembrane domains 1, 3, 6, and 8 (red cylinders) make the core of the protein.
The dopamine binding site is denoted by “S” in a pink hexagon. Purple and green
circles represent sodium, and chloride binding sites, respectively.
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Adapted from Pramod et al. 2012; with permission.
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Although LeuTAa crystal structure showed the binding sites for two sodium ions,
it did not identify the binding site for chloride ion, as LeuTAa does not require chloride to
translocate its substrate. However, biochemical studies elucidate the chloride binding site
to be near the Na1 binding site (39–42).
There are several differences between the prokaryotic and the eukaryotic SLC6
transporters (37). The eukaryotic transporters have 1) a much longer intracellular N- and
C- termini 2) a longer EL2 loop that contains a disulfide bond along with glycosylation
sites and 3) several post-translational modifications. Despite these differences, and the
fact that LeuT does not bind cocaine, it has been used as a template to build DAT
homology models to elucidate the cocaine binding site (43, 44).

	
  
	
  

DAT: Target of Psychostimulants and Therapeutic Drugs
DAT controls the magnitude and duration of dopaminergic neurotransmission.

DA homeostasis is tightly regulated, from its synthesis to its degradation. Several drugs
can attribute to dysregulation of DA homeostasis by increasing synaptic DA levels.
Consequently, post-synaptic DA receptors become stimulated for prolonged time, which
can result into drug associated euphoria, often leading to addiction (45).
Psychostimulants and therapeutic drugs such as cocaine, bupropion (Wellbutrin®,
an antidepressant), methylphenidate (Ritalin®, ADHD medication), and mazindol
(Mazindor®, an appetite suppressant) are classified as strong DAT inhibitors. These
blockers bind to the DAT and inhibit the reuptake on dopamine, which leads to increased
synaptic dopamine levels. In contrast, other psychostimulants such as amphetamine and
methamphetamine are classified as substrates. These substrates compete with the
endogenous substrate, DA, and get transported into the presynaptic neurons through DAT
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where they induce efflux of intracellular DA via reverse transport. The mechanisms of
actions of cocaine and amphetamine are different; however, the net effect of these drugs
is increased synaptic DA levels and prolonged neuron stimulations (46, 47).

	
  
	
  

The Dopamine Hypothesis and Cocaine
Cocaine is a nonselective drug that binds to DAT, SERT and NET and blocks the

reuptake of dopamine, serotonin, and norepinephrine, respectively, and thus elevates their
levels in the synapse. However, the addictive properties of cocaine are attributed to its
ability of elevate DA levels in the nucleus accumbens in the mesolimbic system as stated
in the dopamine hypothesis (48).
To test the dopamine hypothesis a DAT knockout (KO) mouse was created by the
Caron laboratory in 1996. In this model, DA was cleared from the synapse 100 times
slowly than in the WT model, which indicated clearance by diffusion. In the WT model,
the faster clearance is due to the presence of DAT, thus, DA transport via DAT is the
primary mechanism of terminating DA neurotransmission. Additionally, WT and KO
mice injected with cocaine had similar locomotor activity and moreover, cocaine
injections did not show additive hyperlocomoter effect in DAT KO mice (49).
However, Rocha et al. showed DAT KO mice self-administered cocaine and
additionally, Sora et al. showed these mice display cocaine-conditioned place preference
(50, 51). These findings shed a shadow of doubt on the dopamine hypothesis and
possibility of other systems, such as serotonergic system, being involved in rewarding
effects of cocaine. The DAT KO models show several adaptive changes such as altered
DA synthesis, storage, and decreased levels of DA receptors (49). NET and SERT
specific inhibitors have displayed conditioned place preference in DAT KO mice but not
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in WT DAT (52). This suggests that the adaptive changes in DAT KO model could
possibly affect the normal reward pathways.
To evaluate the serotonergic system in reward pathways, SERT KO mice were
generated. These models also displayed cocaine-conditioned place preference (51). But,
combined DAT/SERT KO mice did not display cocaine-conditioned place preference. On
the other hand, NET/SERT KO mice and NET/DAT KO mice display cocaineconditioned place preference (53). All these studies implicate both dopamine and
serotonin systems to explain cocaine reward.
More recently, in 2009, Thomsen et al. used several experimental conditions to
evaluate DAT KO and SERT KO mice in regards to cocaine addiction. Their data support
the dopamine hypothesis and implicate DAT, while eliminating SERT, in reinforcing
effects of cocaine. Discrepancy between studies generated from Rocha et al and Thomsen
et al could be due to the strain of mice used (54).
Several adaptive changes seen due to complete knockout of DAT should be
eliminated with a knockin of mutant DAT. Chen et al. showed that the triple mutation
(L104V/F105C/A109V) in TM domain 2 leads to 70-fold reduction is cocaine inhibition
while retaining 50% DA transport activity compared to WT DAT (55). Cocaineinsensitive DAT knockin model displayed abolished cocaine self-administration and
cocaine reward. These studies re-establish the dopamine hypothesis and implicate the
requirement of functional DAT for cocaine reward (56, 57). Moreover, in humans at least
47% of DAT has to be blocked by cocaine to perceive rewarding effects (58, 59).

	
  
	
  

DAT: Alternating Access Mechanism
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In the late 1950s and the early 1960s, it was proposed that the transporters have
two conformations: one that faces the extracellular space and the other that faces the
intracellular space. By alternating between the two conformations, transporters transport
substrate from the extracellular space to the cytoplasm (60, 61). In 1966, Dr. Oleg
Jardetzky coined the term “alternating access mechanism” to describe such phenomena
(62). Now it is widely accepted that membrane proteins including SLC6 proteins
transport their substrates via the alternative access mechanism (63, 64) (Figure 6).
DAT cycles through outward and inward facing conformations that binds and
releases substrates on the opposite sides of the membrane. When in the outward open
configuration, the cytoplasmic side is sealed off from the aqueous extracellular
environment via the “intracellular gate”. In the similar manner, when in the inward open
configuration, the extracellular side is sealed off from the aqueous intracellular
environment via the “extracellular gate”. Based on LeuT structures, the extracellular gate
in DAT is proposed to be maintained by Arg85 and Asp477 via a water molecule.
Additionally, Tyr156 and Phe320 form aromatic lids that act as a secondary external gate
to prevent access to the central substrate-binding site. The intracellular gate is formed by
Arg60, Ser334, Tyr335, and Asp436. Additionally, tryptophan 63 stabilizes the
intracellular halves of TMs 1 and 6. There are several models that predict how substrates
are translocated intracellularly. One model suggests the unwound regions in TM 1 and 6
act as a hinge and move the intracellular halves of these domains out of the way and
allow the substrate to move in by opening the intracellular gate (37, 64–66). Another
model suggests TMs 1, 2, 6, and 7 form a rigid bundle that rocks back and forth to allow
intracellular and extracellular conformation changes (63). It has been determined that
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Figure 6: Alternating access mechanism of DAT. A) Empty transporter in an outward
farcing configuration. The transporter is facing the extracellular space with open
“extracellular gate” and closed “intracellular gate.” B) Outward facing occupied
transporter. The transporter is facing the extracellular space with open “extracellular
gate” and closed “intracellular gate.” Ions and dopamine bind to their respective
binding sites and that causes conformational change in the transporter leading to the
occluded state. C) Occluded configuration. Ions and substrate are in their respective
binding sites. Both the “extracellular” and “intracellular” gates are closed. D) Inward
facing configuration. The “extracellular” gate remains closed while the “intracellular”
gate opens allowing the translocation of ions and dopamine.
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DAT translocates 1DA: 2Na+: 1Cl- via alternating access mechanism, even though
different models propose different ways of conformational change. Furthermore, DAT
also functions as a “channel” where the intracellular and extracellular gates are both open
and the transporter lacks the stoichiometric ion movements across the membrane. This
“leaking” of substrate is often associated with amphetamine-induced efflux (47, 67).

	
  
	
  

Dopamine and Inhibitor Binding Sites
Crystal structures of LeuTAa in various conformations: outward facing, occluded,

inward facing and inhibitor-bound forms have provided major insights into structural
mechanisms of NSS proteins such as DAT. It was revealed that the substrate-binding site
(S1) is composed of residues from TM domains 1, 3, 6, and 8. In fact, mutagenesis of
many DAT residues in these TM domains, including Phe76, Asp79, Val152, Phe155,
Tyr156, Asn157, Phe319, Val327, and Ser421 reduces dopamine transport (43, 68–76),
indicating the involvement of these residues in substrate recognition or translocation. The
negative charge of Asp79 in TM domain 1 interacts with the positive charge of DA,
which would be present in the cationic form, and aids in binding and transport (68).
Recently, a second substrate-binding site (S2), which is located towards the
extracellular vestibule and above the extracellular gate, has been proposed in LeuT. It has
been reported that binding of a substrate in the S2 site allosterically modulates the release
of ions and substrate from the S1 site and thus aids in substrate translocation. Although
the S2 site could be conserved in mammalian NSS transporters, its role and function are
still controversial (77, 78).
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Just like crystal structures and computational modeling studies based upon the
crystal structures have provided insights into the DA binding sites, these studies have also
provided insights into the cocaine binding sites. Thus far a crystal structure of a cocaine
bound transporter is not available. However, the crystal structures of other inhibitors
bound to LeuT has provided insights into the cocaine binding site. Additionally, there are
several site-directed mutagenesis, substituted cysteine accessibility method, and
quantitative structure activity relationship studies that provide information regarding the
cocaine-binding site (79–84). Similar to the interaction between positively charged DA
and negatively charged D79, the positively charged tropane nitrogen of cocaine interacts
with the negatively charged D79. This salt bridge hypothesis suggests cocaine binds to
the S1 site and competitively inhibits DA binding (43, 68). Numerous other residues
including Leu104, Phe105, Ala109, Asn157, Tyr251, Tyr273, Thr315 Ser320, Thr455,
Ser459 found throughout the core TM domains of DAT have also been implicated in
binding of cocaine and its analogs (55, 76, 85). However, with mutagenesis data it is
difficult to distinguish between direct effects seen due to involvement of those particular
residues with the ligands from indirect effects due to global or macro structural changes.
Additionally, mutagenesis could impact electrochemical gradient by disrupting
stoichiometric ionic movements and thus also impact DA transport.
Not all DAT inhibitors have the positively charged nitrogen group proposed to
interact with D79 (86–88), this suggests the possibility of inhibitors binding differently to
the central binding pocket or to sites other than the S1 site. In fact, inhibitor bound LeuT
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Figure 7: Putative substrate or inhibitor binding sites. S1 is located in the middle of the
transporter half way across the lipid bilayer and below the extracellular gate. S2 is
located towards the extracellular vestibule and above the aromatic lid of extracellular
gate.
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Courtesy of the Henry laboratory, UND.
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crystal structures revealed two putative inhibitor binding sites. Figure 7 represents the
putative inhibitor/ substrate binding sites. Inhibitors that bind to the S1 site block
transport competitively while those that bind to the S2 site block transport noncompetitively (65, 89, 90).
Using LeuT as a template, several DAT homology models have been created to
investigate the inhibitor binding site, most importantly the cocaine binding site. One such
study is by Beuming et al. where several residues were identified to interact with both
DA and the cocaine analog, CFT (2β-carbomethoxy-3β-(4-fluorophenyl) tropane).
Compared to cocaine, CFT has a higher affinity towards DAT that is attributed to the
addition of fluorophenyl moiety at the 3β position of cocaine pharmacophore (Figure 8).
Beuming et al. demonstrated the DA binding pocket in DAT is composed of residues
from the core domain just as in LeuT. There were several notable key interactions
between the protein and the substrate. The protonated amine of DA and the side chain of
Asp79 (TM1) form a salt bridge, the catechol ring of DA and Tyr156 (TM3) form
aromatic-aromatic staking, and the aromatic ring of DA interacts with Phe76 (TM1),
Val152 (TM3), Phe320 (TM6), Phe326 (TM6), Val328 (TM6). Additionally, the
unwound regions of TM1 and TM6 were involved in hydrogen bond interaction with DA.
Several residues in the middle of TMs 1, 3, 6, and 8 are involved directly or indirectly in
coordinating DA (43).
In comparison to DA-DAT interactions, CFT binding involved many of the same
residues interactions. Interaction between CFT and DAT residues are depicted in Figure
8B. The protonated amine of CFT forms a polar interaction with the side chain of Asp79
(TM1), the 2β-methylester moiety interacts with Tyr156 (TM3), and the fluoride atom on
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the phenylfluoride moiety interacts with nitrogen of Asn157 (TM3). Just as with DA, the
tropane ring of CFT interacts with Phe76 (TM1), Val152 (TM3), Phe320 (TM6), Phe326
(TM6), Val328 (TM6). Together these interactions between core residues and CFT
indicate the cocaine binding site overlaps with the substrate binding site. The
computationally predicted model of CFT bound DAT was experimentally supported by
the [3H]CFT binding experiment where the residues shown to interact with CFT were
mutated and the [3H]CFT binding of mutant DATs were analyzed and compared to WT
DAT (43). Difference between CFT affinity in WT and the mutants indicate involvement
of those residues in CFT binding.
Beuming et al. suggested cocaine is a competitive inhibitor and it exerts its
inhibition of DA transport by trapping the transporter in the outward facing conformation.
This observation is in agreement with studies that have shown increased affinity of
cocaine-like compounds in outward open DAT and decreased affinity of cocaine-like
compounds in inward open DAT (91–93).
In contrast, the computational docking of cocaine in DAT homology models built
by Huang et al. suggest cocaine is a non-competitive inhibitor as it binds to the S2 site
(43, 44). Although both Beuming et al. and Huang et al. present experimentally validated
poses, the discrepancy in their conclusions suggest the inhibitor binding poses that are
predicted by the DAT homology models do not necessarily determine the biologically
relevant binding site. Because we lack a crystal structure of cocaine bound NSS
transporter and because the computational pose with the lowest energy does not equate
biologically stable or preferred pose and cocaine bound, the exact binding site(s) of
cocaine on DAT still remain unresolved.
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Figure 8: Structures of dopamine, cocaine and cocaine analog- CFT. (Top) Structures
of inhibitors and substrate. (Bottom) Computationally predicted and biochemically
verified interactions between CFT and DAT residues via backbone (BB) or side chain
(SC) based upon Beuming et al 2008.
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Photoaffinity Labeling
Photoaffinity labeling (PAL) is widely used to identify targets of drugs or to

identify a ligand attachment domain. When crystal structures are not available, PAL can
be used to determine the three-dimensional orientation of the protein (94, 95). Azido
based PALs used in this study contain a photoactivable azido group (N3) that becomes
covalently attached to a residue on a protein when ultraviolent (UV) light induces
resonance reorientation in the phenyl ring attached to the N3 group (Figure 9). Covalent
adduction of the ligand occurs via the N group closest to the phenyl ring.
Several structurally different DAT inhibitors such as cocaine, GBR 12909,
methylphenidate, bupropion, and benztropine have been used as models to derive diverse
PALs which are then used to elucidate the structural properties of DAT. Localization of
several DAT PALs analyzed to date are depicted in Figure 10. These analogs bind near
TMs 1, 3, 6, and 8, suggesting proximity of these domains in three-dimension. Based
upon crystal structures of LeuTAa and dDAT, it is now known that these domains make
up the core of the protein where the substrate-binding site lies.
In this study, we used the combination of tropane-based and non-tropane based
irreversible PALs to study DAT structure. The tropane-based irreversible cocaine PALs
are [125I]RTI 82 ([125I]3β-(p-chlorophenyl)tropane-2β-carboxylic acid, 4´-azido-3´iodophenylethyl ester), [125I]MFZ 2-24 (N-[4-(4-azido-3-(125)I-iodophenyl)-butyl]-2beta-carbomethoxy-3beta-(4-chlorophenyl) tropane), and [125I]JHC 2-48(3-(4’-azido-3’iodo-phenl)-8-methyl-8-aza-bicyclo-[3.2.2]octane-2-carboxylic acid methyl ester) (Figure
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Figure 9: Phenyl azido moiety. Movement of electrons in the phenyl ring upon UV
light activation leads to formation of nitrene. N+ and N- groups are removed as the
nitrene group adducts to C-H or N-H groups of a protein via a nucleophilic attack.
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N=N

Figure 10: Adduction regions of DAT inhibitors. GBR analogs: [125I]AD 96, and
[125I]DEEP; cocaine analog: [125I]MFZ 2-24; and Benztropine analog: [125I]GA 2-34
adduct to TM 1-2. Cocaine Analog: [125I]RTI 82 adducts to TM6. Cocaine analog
[125I]JHC 2-48 adducts TM7-12. Grey shaded TM cylinders represent the core
domains.
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Figure 11: Structures of cocaine and irreversible cocaine analogs, [125I]RTI 82,
[125I]MFZ 2-24, and [125I]JHC 2-48. These structurally similar cocaine analogs differ
based upon where the phenyl azido group is inserted in the cocaine pharmacophore. In
[125I]RTI 82, the phenyl azido group is inserted at the ester moiety. In [125I]MFZ 2-24,
the phenyl azido group is inserted at the tropane nitrogen. In [125I]JHC 2-48, the
phenyl azido group is inserted at the benzoyl moiety.
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11). These cocaine structural analogs share the main pharmacophore with cocaine in that
they all contain the tropane, ester, and benzoyl moieties similar to cocaine. They differ
from one another and from cocaine based upon where phenyl azido group is incorporated
in the cocaine pharmacophore. In [125I]RTI 82, the phenyl azido group is attached at the
ester moiety, in [125I]MFZ 2-24, the phenyl azido group is inserted at the tropane nitrogen
and in [125I]JHC 2-48, the phenyl azido group replaces the benzoyl moiety. [125I]RTI 82,
[125I]MFZ 2-24, and [125I]JHC 2-48 have affinity towards DAT with Ki of 14.5 nM, 33 ±
4.7 nM, and 15.1± 2.2 nM, respectively (96–99).
Once the PALs are covalently attached to the protein upon UV light activation,
DAT is subjected to SDS-PAGE, excised from the gel, and treated with cyanogen
bromide (CNBr), which cleaves Met residues at the C-terminal end. The peptide maps
generated after chemical proteolysis and epitope specific immunoprecipitation are
analyzed to determine the exact incorporation sites of the irreversible analogs. Using
irreversible labeling as a strategy for determining the site of ligand-protein interaction, it
was previously demonstrated that [125I]RTI 82 cross-links to hDAT within a 40-residue
region encompassing TM6 (100) and [125I]MFZ 2-24 cross-links to TM1 between
residues 67 and 80 (101), and [125I]JHC 2-48 cross-links C-terminal to TM7, possibly
between closely spaced Met residues in TM8 or 12.
In contrast, the non-tropane based PALs are relatively unexplored, thus we
evaluated novel methylphenidate based and bupropion based analogs for their ability to
label DAT. Methylphenidate (Ritalin®, Concerta®) is used therapeutically to treat
ADHD. Ritalin® is an immediate-release drug that is rapidly absorbed while Concerta®
has long-acting effects as methylphenidate is slowly released over a period of time.

	
  

38

Bupropion (Wellbutrin®, Zyban®) is widely used as an antidepressant and smoking
cessation agent. The neurochemical mechanisms of bupropion are not completely
understood. Because of their ability to target DAT with high affinity, these drugs are
thought to be a likely target for treatment of cocaine dependency (101,103). Thus, we
evaluated a novel azido-iodo-N-benzyl derivative of threo-methylphenidate analog
([125I]RVDU) and a bupropion analog ([125I]SADU 3-72) for their ability to label DAT as
a first step towards peptide mapping to determine their adduction sites. [125I]RVDU has a
Ki of 363 nM for [3H]CFT binding and IC50 of 2764 nM for [3H]DA uptake (103).
Despite the 7-fold decrease in affinity of the analog compared to bupropion (Ki= 3071
nM vs 441 nM), it was bioactive and thus photoaffinity experiments were conducted
(104). Our data provide first evidence that these novel compounds target DAT in
pharmacological specific manner.

	
  
	
  

Purpose of the Current Study
The monoamine transporters are implicated in several neurological diseases and

disorders including depression, anxiety, addiction, autism spectrum disorder, ADHD, and
Parkinson’s disease. Both therapeutic and abused drugs are thought to target the
transporters and lead to accumulation of dopamine at the synapse. However, not all
classes of DAT inhibitors have reinforcing properties, suggesting the mode of blockade
could impact different behavioral outcomes: addictive or not. In addition, the tremendous
sociological and economical impacts of cocaine addiction make basic understanding of
cocaine binding and transport inhibition at the molecular level an important effort for
future ventures. Thus, understanding cocaine binding in relation to non-addictive DAT
inhibitors could provide critical insights for developing medication strategies toward
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treating cocaine addiction. To aid with potential treatments, we are mapping the DAT
attachment sites/regions for irreversible cocaine analogs [125I]RTI 82, [125I]MFZ 2-24,
and [125I]JHC 2-48. The main differences of these structural analogs, which is the
positions of the added phenylazido moiety, are explored to determine the 3 dimensional
cocaine orientation in the DAT binding pocket via computational modeling. The
phenylazido contact point of these analogs on DAT are distinct and thus, it should
provide us with three different contact points, which will be used to triangulate the
orientation of cocaine pharmacophore in the binding pocket.
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CHAPTER II

MATERIALS AND METHODS
	
  
Materials
Reagents
[125I]MFZ 2-24, [125I]RTI 82, and [125I]JHC 2-48 were synthesized by Dr. Amy
Newman, Dr. Mu-Fa Zou, Dr. Joo Han Cha, Dr. Comfort Boatang, Ms Jianjian Cao from
the National Institute on Drug Abuse. These analogs were radioiodinated by Dr. John
Lever as previously described (96–99). Trypsin, trypsin inhibitor, dopamine, (-)-cocaine,
mazindol, GBR 12909, nomifensine, desipramine, imipramine, and CNBr were from
Sigma-Aldrich (St. Louis, MO). (+)-cocaine was generously provided by Dr. Maarten E.
A. Reith (New York University School of Medicine, New York, NY). [3H]2βcarbomethoxy-3β-(4-fluorophenyl)

tropane

([3H]CFT)

was

from

Perkin

Elmer

(Walthman, MA). [3H]Dopamine and high range Rainbow Molecular Markers, and
Protein A Sepharose beads were from GE Healthcare Life Sciences (Piscataway, NJ).
Lewis Lung Carcinoma Porcine Kidney (LLC-PK1) cells expressing rDAT were kindly
provided by Dr. Gary Rudnick (Yale University, New Haven, CT). The QuickChange
Mutagenesis kit was from Stratagene (La Jolla, CA). Synthetic oligonucleotide primers
were from MWG Operon (Huntsville, AL). Complete Mini Protease inhibitor and
FuGENE HD transfection reagents were from Roche Applied Sciences (Indianapolis, IN).
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Electrophoresis reagents were from Bio-Rad (Hercules, CA). All other chemicals and
reagents were from ThermoFisher (Waltham, MA) or Sigma-Aldrich (St. Louis, MO).
Equipment
Centrifuges
A Beckman Avanti J-25 with 16.250, and 25.50 rotors were used for striatal
membrane preparations and harvesting E. coli cells for protein and plasmid preparation.
Refrigerated Beckman Microfuge R or bench top microfuge 18 were used for general lab
procedures under refrigerated or non-refrigerated conditions. A Beckman J6-MI swinging
bucket centrifuge was used for cell pelleting, preparing Protein A Sepharose beads, and
Protein A cross-linked Sepharose beads.
Electrophoresis, Electroelution, and Dialysis
Sodium dodecyl sulfate poly-acrylamide gel electrophoresis (SDS-PAGE) and
protein transfers were performed using a Bio-Rad Mini-Protean III electrophoresis
apparatus and the Bio-Rad Mini transblot electrophoresis transfer cell, respectively.
Electrophoresis and protein transfer were controlled by Fisher Scientific FB300 power
supply. Gels were dried using a Bio-Rad Model 583 gel dryer. Electroelution of proteins
was performed using the Bio-Rad Model 422 electroeluter with 3.5 kDa cutoff membrane
caps. Electroeluted proteins were dialyzed using ThermoFisher Slide-A-Lyzer® cassettes
with 10 kDa cutoff lining.
Spectroscopy
Bicinchoninic acid (BCA) protein assays were quantified using the Molecular
Devices SpectraMax 190 plate reader and DNA quantification was performed using
Beckman DU640 spectrophotometer. Incorporation of radioactivity during uptake and
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binding experiments were counted using a Packard 1900CA or a Beckman LS6500 liquid
scintillation counter.
Cell Culture, Molecular Biology, and Miscellaneous
Mammalian cell lines were handled in a sterile Nuair Class II type A/B3 laminar
flow hood, and maintained in a Nuair 2700-30 water-jacketed CO2 incubator. An
Eppendorf Mastercycler personal thermocycler was used for all Polymerase Chain
Reaction (PCR) experiments. A polytron PT2100 homogenizer was used to homogenize
rat striatum membranes. A Thermo Savant SpeecVac® evaporator was used to lyophilize
dialyzed and CNBr digested samples. A Fotodyne UV lamp model 3-6000 was used in
photoaffinity labeling studies.
Methods
	
  
	
  
Photoaffnity Labeling- rat striatal membranes
Male and female Sprague Dawley rats (175-300 g) were decapitated and the
striatal tissue was immediately removed and weighed. It was placed in ice-cold sucrosephosphate (SP) buffer (10 mM sodium phosphate, 0.32 M sucrose, pH 7.4) and
homogenized with a Plytron Homogenizer in setting 11 for 12-15 sec. Homogenates were
centrifuged at 20,000 xg for 12 min at 4 °C followed by two washes with SP buffer and
resuspended in Krebs Ringers HEPES (KRH) buffer (25 mM HEPES, 125 mM NaCl, 4.8
mM KCl, 1.2 mM KH2PO4, 1.3 mM CaCl2, 1.2 mM MgSO4, 5.6 mM glucose, pH 7.4) to
20 mg/mL original wet weight (O.W.W). [125I]SADU, [125I]RVDU, and [125I]JHC 2-248
reaction mixtures were prepared in KRH buffer, added to the membranes at various
concentration and incubated for 90-120 min at 0 °C to allow equilibration for reversible
binding. For cocaine displacement studies, 30 µM of (-)-cocaine was added to the binding
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mixture. For pharmacological competition studies, saturating concentrations (1-10 µM)
of non-radioactive transporter inhibitors and substrate were added to the binding mixture.
Irreversible binding of the photoaffinity analogs to DAT was carried out by directly
irradiating the samples with UV lamp (254 nm) for 5 min at a distance of 1 cm. The
photolabeled membranes were washed three times with KRH buffer and centrifugation.
Samples were resuspended in 100 mM Tris-HCl buffer (pH 8.0) for in situ proteolysis or
immunoprecipitation (IP) buffer (50 mM Tris-HCl, 0.1% triton X100, pH 8.0) for
immunoprecipitation.
Photoaffnity Labeling- rDAT and hDAT expressing cells
Wild type and mutant rDAT and hDAT expressing LLC-PK1 cells were plated on
6-well plates and grown to 90-95% confluency. Growth medium was removed, washed
with KRH and incubated with 5 nM raioligand reaction mixtures prepared in KRH buffer
for 1.5 – 2 h at 0 °C to allow equilibration for reversible binding. For cocaine
displacement studies, 30 µM of (-)-cocaine was added to the binding mixture. The
ligands were irreversibly bound onto DAT by direct irradiation with UV (254 nm) light
for 5 min at a distance of 1 cm. Photolabeled cells were washed twice with KRH buffer
and solubilized with radioimmunoprecipitation assay (RIPA) buffer (1% Triton X-100,
0.1% SDS, 125 mM sodium phosphate, 150 mM NaCl, 2 mM EDTA, 50 mM sodium
fluoride, pH 7.4) with Complete Mini protease inhibitor for 30-45 min at 0 °C. Lysates
were centrifuged at 20,000 xg for 15 min at 4 °C, supernatants were collected and further
analyzed.
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In situ Trypsin Proteolysis
Photolabeled rat striatal membranes were treated with 10-200 µg/mL of trypsin at
37 °C for 25 min. Equal concentration of trypsin inhibitor was added to the reaction
mixture and centrifuged at 20, 000 xg for 12 min at 4 °C to quench the reaction. The
pellets were solubilized and subjected to immunoprecipitation.
Gel Purification, Electroelution, and Dialysis
Solubilized radiolabeled DATs were subjected to 8% SDS-PAGE. Gels were
dried and subjected autoradiography for 12-16 h. The ~80 kDa labeled bands associated
with DAT were excised and rehydrated in 1X SDS-PAGE running buffer (25 mM Tris,
192 mM Glycine, and 0.1% SDS). Rehydrated gel pieces were subjected to electroelution
at 10 mA/tube for 6 h. Samples were dialyzed against 4 L of MilliQ water for 12-15 h.
Radioactivity in samples was assessed by liquid scintillation counting and samples
containing equal amounts of radioactivity were lyophilized in a SpeedVac®.
In solution CNBr digestion
Lyophilized samples were incubated with 70% formic acid or with 0.1 mL of 1
M CNBr prepared in 70% formic acid for 24 h at 22 °C. The reactions were quenched by
the addition of 900 µL of MilliQ water and lyophilization followed by three washes with
MilliQ water and subsequent lyophilization in a SpeedVac® concentrator. The final
samples were resuspended in IP buffer and either subjected to IP or acetone precipitation.
Acetone Precipitation
Samples were resuspended in 4SB buffer (50 mM Tris, 5 mM EDTA, 4% SDS,
pH 7.4) and acetone in a 1:4 ratio followed by centrifugation at 20,000 x g for 15 min.
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Pellets were solubilized in 1X sample buffer and subjected to SDS-PAGE and
autoradiography.
Immunoprecipitation, Electrophoresis, Autoradiography, and Western Blot
Solubilized radiolabeled DAT or DAT fragments were subjected to epitope
specific immunoprecipitation using antiserum 16 generated against amino acids 42-59 or
antiserum C-20 generated against the C-terminal. For cross-linking Ab to protein A
sepharose, beads were hydrated and washed three times with triethanolamine (TEA) (0.2
M TEA, pH 8.0). Beads were incubated with polyclonal antibody for 45 min at 22 °C and
washed twice with TEA buffer; antibody was cross-linked to the beads by incubation
with dimethyl pimelimidate (DMP) for 45 min at 22 °C. The beads were washed twice
with 100 mM Tris pH 8.0, rinsed with IP buffer and resuspended and stored in IP buffer
containing 0.05% sodium azide. Alternatively, protein A sepharose beads were hydrated
and rinsed three times with TEA buffer followed by washes with IP buffer.
Samples were incubated with either beads + antibody or with cross-linked beads
for 3 h at 22 °C or alternatively, overnight at 4°C while rotating. Samples and beads were
washed four times with IP buffer and eluted with 2X sample buffer. Immunoprecipitated
samples were electrophoresed on SDS-PAGE 4-20%, 10-20% or 8% gels followed by
autoradiography using Hyperfilm™ MP for 2-8 days at -80 °C. High-range Rainbow
Markers were used as molecular mass standards.
For Western blot, proteins were transferred to PVDF membranes following SDSPAGE. rDAT and hDAT specific primary antibodies were prepared in blocking buffer
(3% BSA/ 1% Tween/ 1X PBS) at a 1:1000 ratio. Secondary antibodies were prepared in
blocking buffer at 1:5000 ratio. Immunoreactive bands were visualized using Immuno-
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Star AP substrate (Bio-Rad) and quantified using a Bio-Rad Chem Doc XRS system and
Quantity One 4.6.7 software (Bio-Rad).
[3H]CFT Binding
WT and mutant rDAT and His-hDAT were grown in 24-well plates until 80-90%
confluent. Cells were washed twice with 500 µL of ice-cold KRH and incubated with 10
nM [3H]CFT in KRH for 2 h on ice in a final volume of 500 µL. Binding was performed
in triplicate with nonspecific binding determined with 15 µM mazindol. The reactions
were quenched by washing cells twice with ice-cold KRH followed by solubilization of
cells with RIPA buffer containing protease inhibitors. Lysates were assessed for
radioactivity by liquid scintillation counting at 52% efficiency and for protein content by
the BCA method.
[3H]Dopamine Uptake
WT and mutant rDAT and His-hDAT were grown in 24-well plates until 80-90%
confluent. Cells were rinsed twice with 500 µL of 37 °C KRH buffer. Uptake was
performed in a final volume of 500 µL KRH with nonspecific uptake determined with
100 µM (–)-cocaine. Assays were initiated by addition of 10 nM [3H]DA plus 3 µM DA
and allowed to proceed for 8 min at 37 °C. The reactions were terminated by washing
cells twice with ice-cold KRH followed by solubilization of cells with RIPA buffer
containing protease inhibitors. Lysates were assessed for radioactivity by liquid
scintillation counting and for protein content by the BCA method.
QuickChange® Site-Directed Mutagenesis, Plasmid Transformation, and Transfection
Wild Type (WT) 6xHis-human hDAT in apcDNA 3.1/His and WT rDAT in
pcDNA 3.0 were used as starting templates for mutagenesis. Stratagene design primer
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software was used to design oligonucleotide primers, which were ordered from MWG
operon. QuickChange® method was used to mutant selected residues in order to insert or
eliminate CNBr cleavage sites (methionine residues). A 50 µL reaction mixture included
5 µL of 10X reaction buffer (100 mM KCl, 100 mM (NH4)2SO4, 200 mM Tris-HCl, 20
mM MgSO4, 1% Triton X-100, 1 mg/mL nuclease free BSA, pH 8.8), 8 µL of Template
DNA (5 ng/µL), 1.25-1.60 µL of oligonucleotide forward and reverse primers (125 ng), 2
µL of dNTP mix, 32.5 – 31.8 µL of double distilled DNAse free H2O. Addition of 1 µL
of pfu Turbo or pfu Ultra DNA Polymerase (2.5 U/µL) initiated the polymerase chain
reaction (PCR). PCR cycling parameters included denaturation, annealing, and primer
extension. Denaturation required heating the DNA to 95 ºC for 1 min to render it singlestranded. The annealing step was performed at 55 ºC for 1 min and primer extension was
done at 68 ºC for 8 min followed by 15 repeated denaturation, annealing, and primer
extension cycles. Supercoiled double stranded template DNA was degraded by
incubation with 1 µL of DpnI restriction enzyme for 18 h at 37 ºC. The generated plasmid
was transformed into Stratagene Giga competent E coli cells. 1-4 µL of ligation mixture
was added to 25 µL of competent cells. Cells were placed on ice for 5 min and heat
shocked for 30 sec at 42 ºC on a heat block. Tubes were placed on ice for 2 min and 250
µL of SOC media was added and cells were plated on carbenicillin resistant agar plates
for > 16 h at 37 ºC. The plasmid was isolated using PureYield® Plasmid miniprep
System (Promega). DNA was quantified via Epoch microspot spectrometry and sent to
verify sequencing to Northwoods DNA (Solway, MN) or MWG operon (Birmingham,
AL). LLC-PK1 cells were transfected with His-hDAT and rDAT mutants at 3:2 FuGENE
HD to DNA ratio. Cells were selected against G418 and stably expressed DATs. WT and
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mutant r/hDAT cells were maintained in a humidified chamber with 5% CO2 at 37°C in
α-minimum essential medium (AMEM; 5% fetal bovine serum, 2 mM L-glutamine, 200
µg/mL G418, and 100 µg/mL penicillin/streptomycin) for LLC-PK1 cells.
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CHAPTER III

RESULTS

	
  
	
  

Identification of [125I]RTI 82 Adduction Site on hDAT
Previous studies demonstrated that [125I]RTI 82 cross-links to hDAT within a 40-

residue region encompassing TM6 (100). Based upon LeuTAa and dDAT crystal
structures, unwound regions in TM domains 1 and 6 accommodate substrate binding and
possibly inhibitor binding as well; therefore we started our initial screenings by targeting
residues around the unwound region. Additionally, our collaborators (Dr. Henry, Dr.
Sharma, and Dr. Akula Bala) computationally predicted two residues near the unwound
region, Phe320 and Phe326, as possible sites of adduction. These predictions were made
by identifying low energy RTI 82 poses that satisfied the two main biological constraints:
interaction between the N3 group and a residue in TM6; and an interaction between the
tropane N and the Asp79 side chain. Interaction was defined if the residues were within 5
Å of one another.
We sought to validate the prediction from computational modeling that Phe320
was the likely site of RTI 82 adduction. For this we generated methionine (Met)
substitutions of residues flanking Phe320 in hDAT for use in CNBr peptide mapping. To
further strengthen the interpretation of the proteolysis patterns, we introduced all TM6
Met substitutions in an M272L background to eliminate Met272 as a CNBr proteolysis
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site (100). In hDAT, Met272 is the only Met between TM2 and TM7, thus in the M272L
background, the introduction of Mets into TM6 would result in generation of a CNBr
fragment of ~50 kDa that would extend from TM2 (Met106, Met111, or Met116) to the
inserted Met, or a CNBr fragment of ~6 kDa that would extend from the inserted Met to
Met371 in TM7 (Figure 12). The masses of the labeled CNBr fragments produced thus
indicate the relative positions of the inserted Mets and the site of [125I]RTI 82 adduction.
For ease of discussion, we refer to the double mutants with TM6 Met substitutions in the
M272L background solely by the TM6 mutation (e.g. V318M hDAT indicates
M272L/V318M hDAT) and to the CNBr fragments by the flanking Mets, although the Nterminus of each fragment is the residue following a proteolyzed Met.
We mutated all residues between V318 and I330 to methionine, except for
glycines. Most of the glycine residues examined thus far are shown to be important for
DAT activity. Mutations of Gly at positions 323, 325 and 327 either have loss of or
greatly reduced plasma membrane expression (105, 106). The mutants generated for this
study (V318M, C319M, F320M, S321M, L322M, V324M, F326M, V328M, L329M and
I330M) were stably expressed in LLC-PK1 cells and assessed for expression, [3H]DA
uptake, [3H]CFT binding, and cocaine displaceable [125I]RTI 82 labeling. Based upon the
activities and expression levels, we chose to use V318M, C319M, F320M, S321, L322M,
V324M, I330M extensively for peptide mapping studies to identify the [125I]RTI-82
adduction site.
The expression levels determined by immunoblotting of the selected mutants
ranged from ~50-100% of WT DAT (Figure 13A), with all showing expression of full
length, mature protein. When normalized for transporter expression levels, the mutants
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Figure 12: Schematic diagram of hDAT with methionines. A) Schematic diagram of
hDAT with endogenous Met residues represented by black dots. Glycosylation sites
are represented in extracellular loop 2. B) Cyanogen bromide cleavage at Met in TM5
and TM7 produce an 11 kDa fragment (red shading), which represents the [125I]RTI 82
labeled fragment. C) Strategy for identifying [125I]RTI 82 adduction site. We
introduced all TM6 Met substitutions in an M272L background to eliminate Met272
as a CNBr proteolysis site. In hDAT, Met272 is the only Met between TM2 and TM7,
thus in the M272L background, the introduction of Mets into TM6 would result in
generation of a CNBr fragment of ~50 kDa that would extend from TM2 (Met106,
Met111, or Met116) to the inserted Met (blue shaded region), or a CNBr fragment of
~6 kDa that would extend from the inserted Met to Met371 in TM7 (green shaded
region).
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showed [3H]DA uptake values that ranged from ~20-60% of the WT protein, except for
F320M and S321M, which exhibited <10% of the WT activity (Figure 13B). Loss of
transport in these mutants is consistent with their functional roles, as Phe320 is proposed
to act as a substrate pocket gating residue and Ser321 coordinates Na+ at the Na1 site (37,
107). [3H]CFT binding for the mutants was impacted less than transport, ranging from
~60-90% of WT levels when normalized for expression (Figure 13B), and all forms
showed [125I]RTI 82 photoaffinity labeling that was fully blocked by cocaine (Figure
13C), indicating that the mutations did not substantially disrupt the cocaine binding
pocket.
For peptide mapping studies, the photolabeled proteins were gel purified and
subjected to treatment with vehicle (formic acid) or CNBr, followed by SDSPAGE/autoradiography. Within each experiment, equal amounts of radioactivity for WT
and mutant forms were analyzed to allow for direct comparison of peptide fragment
production. Figure 14 shows a compilation of representative peptide maps produced from
three or more independent replicates for each mutant, with schematic diagrams indicating
the primary sequence origin of labeled fragments and site of [125]RTI 82 adduction (star
symbol). Full length, unproteolyzed DAT migrates at ~90 kDa (odd numbered lanes)
with no low Mr fragments observed. Aggregates seen at ≥180 kDa are most likely
induced by the formic acid treatment, as they were not seen in samples subjected directly
to electrophoresis. CNBr treatment of WT hDAT produced a labeled fragment of ~11
kDa (lane 2; arrow a) as we previously demonstrated (100), that corresponds to the region
between Met272 and Met371 (calculated mass 10.6 kDa, shaded region in schematic
diagram a), as well as larger fragments that likely arise from missed cleavage of Met272.
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Figure 13: Characterization of Met-substituted hDATs. (A) LLC-PK1 cells expressing
the indicated DAT forms were lysed and equal amounts of protein immunoblotted for
DAT. (B) LLC-PK1 cells stably expressing the indicated DAT forms were assayed for
[3H]DA uptake (filled bars) or [3H]CFT binding (open bars). Values shown (means of
± S.E.) are normalized for total DAT protein and expressed relative to the WT level
(100%). #, p<0.05 vs. WT binding; ***, p<0.001 vs. WT uptake, by ANOVA with
Dunnett’s Multiple Comparison Test. (C) Autoradiograph of the indicated hDAT
forms photolabeled with [125I]RTI 82 in the presence or absence of 30 µM(–)-cocaine.
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CNBr treatment of [125I]RTI 82-labeled V318M and C319M hDATs produced fragments
of ~6 kDa (lanes 4 and 6; arrow b) that are consistent with peptides extending from the
inserted Mets to Met371 (calculated masses ~5.6 kDa; shaded region in schematic
diagram b), with higher Mr fragments in these samples also indicating missed cleavage of
the inserted Mets. In contrast, mutants F320M, S321M, L322M, V324M, and I330M
produced only the ~50 kDa fragments (arrow c) that correspond to the shaded region in
schematic diagram c (calculated peptide masses ~22.4-23.3 kDa, with additional ~25 kDa
of mass contributed from EL2 N-linked carbohydrate), with no production of fragments
with masses <8 kDa. These cleavage patterns indicate that ligand adduction occurs Cterminal to V318M and C319M and N-terminal to F320M, S321M, L322M, V324M, and
I330M. Because CNBr proteolyzes peptide bonds on the C-terminal side of Mets, the the
[125I]RTI 82 adduction site is Phe320. These results also rule out a significant level of
[125I]RTI 82 adduction to other residues within this stretch of TM6, including Phe326, an
interaction that was suggested by computational modeling.
Although CNBr proteolysis of [125I]RTI 82-labeled F320M, S321M, L322M,
V324M, and I330M did not produce the ~6 kDa fragments seen in V318M and C319M
hDATs, some lightly labeled fragments of ~8-10 kDa were seen in some digests (Figure
14A). These fragments likely originate from adduction of [125]RTI 82 to a different region
of the DAT primary sequence, as we have obtained preliminary evidence from antibodybased mapping that a small fraction of [125I]RTI 82 adduction occurs C-terminal to TM6
(unpublished data). Multi-site incorporation of DAT photoaffinity labels has been
previously demonstrated (108), and likely occurs due to the proximity of the TM domains
in the protein core in conjunction with small fluctuations in phenylazido moiety
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Figure 14: CNBr mapping of [125I]RTI82-labeled TM6 DAT mutants. The indicated
DAT forms were photolabeled with [125I]RTI 82 and gel purified. Equal amounts of
radioactivity were treated with vehicle (formic acid; odd numbered lanes) or CNBr
(even numbered lanes) and analyzed by SDS-PAGE/autoradiography. Unproteolyzed
DAT is present in odd numbered lanes at ~90 kDa. CNBr proteolysis of the WT
protein produces a fragment of ~11 kDa (lane 2, arrow a) that corresponds to the
shaded region in schematic diagram a. CNBr treatment of V318M and C319M hDATs
produces fragments of ~6 kDa (lanes 4 and 6, arrow b), that correspond to the shaded
region in schematic diagram b. CNBr treatment of the remaining constructs produced
fragments of ~50 kDa (lanes 8, 10, 12, 14, and 16, arrow c) that correspond to the
shaded region in schematic diagram c, but no fragments of < 8 kDa. The star symbol
represents the site of ligand adduction at Phe320. Filled circles in the schematic
diagram represent Mets present in the construct.
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orientation during the photoactivation process. However, the significantly lower labeling
intensity of this secondary site relative to that occurring in TM6 indicates that Phe320 is
the predominant site of adduction.
Identification of the [125I]MFZ 2-24 Adduction Site on rDAT
Previous studies demonstrated that [125I]MFZ 2-24 cross-links to DAT within a
13-residue region in TM1 between Ile67 and Leu80 (101). To further narrow the
adduction site, we implemented CNBr peptide mapping analyses with epitope specific
immunoprecipitation. In this approach, upon CNBr treatment the inserted Met in TM1
would divide this domain in two halves. Immunoprecipitation of a labeled fragment with
Ab16 would indicate adduction is N-terminal to the inserted Met. Likewise, the absence
of a photolabeled fragment in the immunoprecipitated sample would indicate adduction is
C-terminal to the inserted Met (Figure 15). Therefore, we inserted Met in place of several
residues: Leu70, Val73, Ile74, Gly75, Phe76, Ala77, Val78, Asp79, and Leu80, one at a
time.
After generating stably expressing rDAT and hDAT mutants in LLC-PK1 cells,
we accessed for [3H]DA uptake, [3H]CFT binding, expression level, and cocaine
displaceable [125I]MFZ 2-24 labeling. Figure 16 represents an autoradiography of several
mutants labeled with [125I]MFZ 2-24 in the presence or absence of cocaine. [125I]MFZ 224 labeled cells were lysed, immunoprecipitated with Ab 16 and subjected to
autoradiography. [125I]MFZ 2-24 labeling of WT, L80M, V78M, and A77M DATs were
displaced by cocaine, however, F76M, G75M, and I74M DAT labeling was not displaced
by cocaine and was also weakly labeled compared to the WT. This indicates
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Figure 15: Approach to identify the [125I]MFZ 2-24 adduction site. Black dots
represent endogenous Mets while black dot with M represents inserted Met. Green
bolded line represents epitope for Ab 16. Generation of an immunoprecipitable
fragment indicates adduction is N-terminal to the inserted Met (green shaded region).
Lack of an immunoprecipitable fragment indicates adduction is C-terminal to the
inserted Met (blue shaded region).

	
  

61

Epitope 16

	
  

62

Figure 16: The [125I]MFZ 2-24 photoaffinity labeling of WT and rDAT mutants in the
presence

or

absence

of

cocaine.

Photolabeled

DATs

were

lysed

and

immunoprecipitated with Ab 16 and subjected to autoradiography. [125I]MFZ 2-24
labeling of WT, L80M, V78M, and A77M is displaced by cocaine. However,
[125I]MFZ 2-24 labeling of F76M, G75M, and I74M was not displaced by cocaine and
was also weakly labeled compared to the WT.
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the inserted Met mutations impacted the cocaine binding pocket. Additionally, Phe76 is
involved in binding substrate and cocaine (43, 69). Based upon functionality of the
mutants, we chose to further analyze L70M, V73M, A77M, V78M and L80M rDATs for
peptide mapping.
For peptide mapping studies, the photolabeled proteins were gel purified and
subjected to treatment with vehicle (formic acid) or CNBr. Following quenching of CNBr
digestion, samples directly subjected to SDS- PAGE/autoradiography are denoted as total
while samples immunoprecipitated with Ab 16 prior to SDS- PAGE/autoradiography are
denoted as immunoprecipitation. Within each experiment, equal amounts of radioactivity
for WT and mutant forms were analyzed to allow for direct comparison of peptide
fragment production. Figure 17 shows a compilation of representative peptide maps
produced from two or more independent replicates for each mutant, with schematic
diagrams indicating the primary sequence origin of labeled fragments and site of
[125]MFZ 2-24 adduction (star symbol).
The left panel denotes the fragments generated from CNBr digestion of [125I]MFZ
2-24 labeled WT and mutant DATs. Full length, unproteolyzed DAT migrates at ~90 kDa
(odd numbered lanes) with no low Mr fragments observed. Aggregates seen at ≥180 kDa
are most likely induced by the formic acid treatment, as they were not seen in samples
subjected directly to electrophoresis. CNBr treatment of WT rDAT produced a labeled
fragment of ~12kDa (lane 2; arrow a) that was immunoprecipitated with Ab 16 (lane 10)
as we previously demonstrated (101). A ~12kDa fragment present in lanes 2 and 10
corresponds to the region between Met1/11 and Met106 (shaded region in left schematic
diagram). CNBr treatment of [125I]MFZ 2-24 labeled L80M rDAT produced a fragment
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of ~8 kDa, which was also present in IP samples (lanes 4 and 12; arrow b). This is
consistent with peptides extending from N-terminus to L80M (shaded region in middle
schematic diagram). Additionally, the presence of this fragment is consistent with our
previously published data (101). The higher Mr fragments (WT sized fragment) in lane 12
indicate missed cleavage at L80M. This suggests [125I]MFZ 2-24 adduction occurs Nterminal to L80M. Fragments generated by cleavage at V78M and A77M were not
immunoprecipitated by Ab 16 (lanes 14 and 16), because cleavage at the inserted Met
separated epitope 16 from the adduction site. This indicates the adduction is C-terminal to
the inserted Met. Thus, [125I]MFZ 2-24 adduction occurs either at Asp79 or Leu80.
Asp79 is a highly conserved essential residue involved in DA transport and as a result its
mutation along with mutation of Leu80 have been shown to impact DA binding (43, 68).
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Figure 17: CNBr mapping of the [125I]MFZ 2-24-labeled TM1 DAT mutants. The
indicated DAT forms were photolabeled with the [125I]MFZ 2-24 and gel purified.
Equal amounts of radioactivity were treated with vehicle (formic acid; odd numbered
lanes) or CNBr (even numbered lanes) and analyzed by SDS-PAGE autoradiography
following immunoprecipitation by Ab 16 when needed. CNBr treatment of WT rDAT
produced a labeled fragment of ~12 kDa (lane 2; arrow a) that was
immunoprecipitated with Ab 16 (lane 10) (shaded region in left schematic diagram).
CNBr treatment of the [125I]MFZ 2-24 labeled L80M rDAT produced fragment of ~8
kDa, which was also present in IP samples (lanes 4 and 12; arrow b) (shaded region in
middle schematic diagram). This suggests the [125I]MFZ 2-24 adduction occurs Nterminal to L80M. Fragments generated by cleavage at V78M and A77M were not
immunoprecipitated by Ab 16 (lanes 14 and 16), because cleavage at the inserted Met
separated epitope 16 from the adduction site. This indicates the adduction is Cterminal to the inserted Met. Thus, the [125I]MFZ 2-24 adduction occurs either at
Asp79 or Leu80.
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Pharmacological Profile of [125I]JHC 2-48
The third irreversible cocaine PAL we analyzed in this study was [125I]JHC

2-48. This analog is structurally identical to RTI-82 and MFZ 2-24, with an exception of
phenylazido positioning on the cocaine pharmacophore. This analog has not been
thoroughly investigated, thus, we started our evaluation by determining its
pharmacological specificity towards DAT. His-hDAT expressing LLCPK1 cells were
labeled with the analog and incubated in the absence or presence of several known DAT
inhibitors and the physiological substrate, DA, along with NET and SERT inhibitors
(Figure 18). Cells lysates were immunoprecipitated with anti-His antibody to isolate
hDAT. Various DAT inhibitors (-)-cocaine, mazindol, GBR 12909, and nomifensine
were able to displace [125I]JHC 2-48 labeling of hDAT. Additionally, the endogenous
substrate, DA, also displaced [125I]JHC 2-48 labeling of hDAT. However, (+)-cocaine,
NET inhibitor desipramine and SERT inhibitor imipramine were unable to displace
[125I]JHC 2-48 labeling of hDAT. These results demonstrate pharmacological specificity
of [125I]JHC 2-48 towards DAT.
Trypsin Digestion and Epitope Specific Immunoprecipitation of
[125I]JHC 2-48 Labeled DAT
CNBr digestion of [125I]JHC 2-48 labeled WT DAT produced a fragment that was
not visible in SDS-PAGE. Lack of a fragment indicated the adduction of [125I]JHC 2-48
most likely occurs between the two closely spaced Met residues possibly in TM8 or 12
thus, the generated fragment would be too small to detect by SDS-PAGE. However,
recent analyses of [125I]JHC 2-48 labeled WT DAT cleaved with CNBr generated a ~9
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Figure 18: Pharmacological profile of hDAT labeled with [125I]JHC 2-48. His-hDAT
expressing cells were labeled with [125I]JHC 2-48 in the presence and absence of DAT,
NET and SERT inhibitors along with endogenous substrate DA. Cells were lysed,
immunoprecipitated with anti-His antibody and subjected to autoradiography. [125I]JHC
2-48 labeling of hDAT was displaced by DAT inhibitors (-)-cocaine, mazindol, GBR
12909, and nomifensine. Additionally, the endogenous substrate, DA, also displaced
[125I]JHC 2-48 labeling of hDAT. However, an inactive isomer of cocaine ((+)cocaine), NET inhibitor desipramine and SERT inhibitor imipramine were unable to
displace [125I]JHC 2-48 labeling of hDAT. This represents pharmacological specificity
of [125I]JHC 2-48 towards DAT.
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kDa fragment. This data indicates our previous hypothesis is not valid. Thus, we analyzed
trypsin digestion and epitope specific immunoprecipitation of [125I]JHC 2-48 labeled rat
striatal membrane.
Trypsin cleaves at positively charged Lys and Arg; specifically, Arg218 on DAT
is readily accessible for trypsin cleavage, which divides photolabeled DAT into two
halves. Immunoprecipitation of a ~45 kDa photolabeled fragment by the N-terminal Ab
would indicate adduction of the analog occurs N-terminal to Arg218, in TMs 1-3. A ~45
kDa fragment incorporates all residues N-terminal to Arg218, which accounts for ~20
kDa fragment, and glycosylation in EL2, which adds ~ 25 kDa mass to the fragment.
However, immunoprecipitation of a ~32 kDa fragment by a C-terminal specific Ab
would indicate adduction of the analog occurs C-terminal to Arg218, in TMs 4-12 (109)
(Figure 19).
Trypsin digestion and epitope specific immunoprecipitation allows us to
determine a broad region where the ligand adducts, thus, rat striatal membranes labeled
with [125I]JHC 2-48 were subjected to trypsin digestion and epitope specific
immunoprecipitation to determine the region of [125I]JHC 2-48 incorporation. Figure 20
represents trypsin peptide map of [125I]JHC 2-48 labeled rDAT. N-terminal Ab did not
immunoprecipitate a photolabeled fragment, which suggests adduction does not occur in
TMs 1-3. Presence of ~12 kDa fragment in the C-terminal Ab immunoprecipitated
sample of trypsin digested DAT indicates adduction occurs within 12 kDa of the epitope
C-20. Trypsin cleavage at a cut site in IL5 would result in a production of ~12 kDa
fragment. Thus, this indicates [125I]JHC 2-48 adducts in TM 11-12. However, we cannot
rule out the possibility of [125I]JHC 2-48 adduction to TMs 4-10, since there are several
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Figure 19: rDAT sequence with trypsin cleavage site at Arg218. Immunoprecipitation
of a ~45 kDa photolabeled fragment (yellow) by the N-terminal specific antibody
(epitope 16 region; represented by green shaded residues) indicates adduction of the
analog occurs N-terminal to Arg218, in TMs 1-3. A ~45 kDa fragment incorporates all
residues N-terminal to Arg218, which account for ~20 kDa fragment, and
glycosylation in EL2, which adds ~25 kDa mass to the fragment. Immunoprecipitation
of a ~32 kDa fragment (blue) by a C-terminal specific antibody (epitope C-20 region;
represented by pink shaded residues) indicates adduction of the analog occurs Cterminal to Arg218, in TMs 4-12.
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Figure 20: Trypsin digestion and epitope specific immunoprecipitation of [125I]JHC 248 labeled rat striatal DAT. Lack of a small Mr photolabeled fragment in the Nterminal Ab pull down lane (2nd lane), indicates adduction does not occur in TMs 13. The presence of a ~12 kDa fragment in the C-terminal Ab immunoprecipitated
sample of trypsin digested DAT (4th lane) indicates adduction occurs within 12 kDa
of the epitope C-20. Trypsin cleavage at either cut site in IL5 would result in a
production of a ~12 kDa fragment. Thus, this indicates [125I]JHC 2-48 likely adducts
in TM 11-12
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trypsin cleavage sites present all across DAT and cleavage at those sites would separate
the adduction site from the epitope region.
Photoaffinity Labeling of DAT With Methylphenidate Analog ([125I]RVDU)
	
  

Methylphenidate is a DAT blocker used therapeutically to treat ADHD. Thus far,
its binding site on DAT is not determined. Additionally, non-‐tropane	
   based	
   PALs	
   are	
  
relatively	
   unexplored,	
   thus,	
   we	
   analyzed	
   a	
   novel	
   methylphenidate	
   analog	
  
[125I]RVDU to determine its specificity towards DAT as a initial step towards peptide
mapping.
Rat striatal membranes were labeled with 30 nM of [125I]RVDU in the presence
and absence of 10 mM or 100 mM of β-CFT and D-MPH (Figure 21). Labeled proteins
were immunoprecipitated with DAT specific Ab and subjected autoradiography. Labeling
of DAT with [125I]RVDU was set at 100%. Incorporation of the ligand was reduced by
both β-CFT and D-MPH by 75-90% in a dose dependent manner. This indicates
pharmacological specificity of [125I]RVDU for DAT. Most importantly, this is the first
successful example of a DAT PAL based on a MPH scaffold (103).
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Figure 21: Photoaffinity labeling of DAT with [125I]RVDU. Structures of MPH and
RVDU are depicted on top. Rat striatal membranes were photoaffinity labeled with 30
nM [125I]RVDU in the absence or presence of 10 µM or 100 µM β-CFT or D-MPH.
Membranes were solubilized and DATs were immunoprecipitated followed by SDSPAGE and autoradiography. The relevant portion of a representative autoradiograph is
pictured followed by a histogram that quantifies relative band intensities. Mean ± SE
of three independent experiments is shown; ***p<0.001 versus control.

	
  

78

MPH

RVDU

Published in Bioorganic and Medicinal Chemistry. Lapinsky et al. 2011
	
  
	
  

79

	
  

Photoaffinity Labeling of hDAT with Bupropion Analog ([125I]SADU 3-72)
Bupropion (Wellbutrin®, Zyban®) is widely used as an antidepressant and

smoking cessation agent. Because of its higher affinity towards DAT, bupropion is
thought to be a likely target for treatment of cocaine dependency. However,
neurochemical mechanisms of bupropion are not completely understood (103). Thus, we
analyzed a novel bupropion analog ([125I]SADU 3-72) for DAT photoaffinity labeling, as
a first step towards understanding its interaction with DAT at the molecular level.
hDAT cells were photoaffinity labeled with [125I]SADU 3-72 in the absence or
presence of 10 µM or 100 µM (±)-bupropion or (-)-cocaine (Figure 22). Cells were lysed
and immunoprecipitated, followed by SDS-PAGE/autoradiography. Labeling of DAT
with [125I]SADU 3-72 was set at 100%. Incorporation of the ligand was blocked by both
(±)-bupropion or (-)-cocaine by 40-70% in a dose dependent manner. This indicates
pharmacological specificity of [125I]SADU 3-72 for DAT. Most importantly, this is the
first successful example of DAT PAL based on a bupropion scaffold.
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Figure 22: Photoaffinity labeling of DAT with [125I]SADU 3-72. Structures of
bupropion and SADU 3-72 are depicted on top. LLC-PK1 expressing His-hDAT were
photoaffinity labeled with [125I]SADU 3-72 in the absence of presence of 10 µM or
100 µM (±)-bupropion or (-)-cocaine. Cells were solubilized and DATs were
immunoprecipitated followed by SDS-PAGE and autoradiography. The relevant
portion of a representative autoradiograph is pictured followed by a histogram that
quantifies relative band intensities. Mean ± SE of three independent experiments is
shown; ***p<0.0001 versus control; **p<0.001 versus control.

	
  

81

Published in Bioorganic and Medicinal Chemistry Letters. Lapinsky et al. 2012

	
  

82

CHAPTER IV

DICUSSION
	
  
The kinetic interactions of DAT with cocaine and its analogs are complex,
resulting in high and low affinity binding states (110, 111) and competitive and noncompetitive uptake inhibition (112, 113). We currently lack a complete mechanistic
understanding of these properties, as some mutagenesis and comparative modeling
studies support the interaction of cocaine at S1 where it could suppress transport by
competing with substrate for key interactions (43, 114). Furthermore, two things cannot
occupy the same 3D space. On the other hand, some studies support binding near S2
where it could allosterically stabilize an inactive state of the transporter (44, 115–117). It
has been proposed that these binding modes are not mutually exclusive and that cocaine
may initially bind near the S2 site before transitioning to S1 following conformational
changes (44, 115).
The current collection of LeuT and dDAT crystal structures supports multiple
binding sites for substrates and inhibitors (37, 65, 77, 90, 107, 117–122) and both
allosteric and competitive inhibition mechanisms (64, 65, 74, 77, 89, 117–120, 123–129).
Understanding DAT-cocaine interaction at the molecular level is essential in order to
develop any drugs to treat cocaine dependency. However, to date, no high-resolution
crystal structures of cocaine-bound SLC6 transporters have been obtained (64, 123, 130)
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thus, the exact cocaine binding site(s) on DAT and their relationships to the various
kinetic states remain unresolved.
As a positive function approach to these issues we used irreversible cocaine
analogs, [125I]RTI 82, [125I]MFZ 2-24, [125I]JHC 2-48, as probes for physical
identification of ligand interaction sites (100, 101, 131). We identified the attachment site
of [125I]RTI 82 to Phe320. This is the first identification of a specific photoaffinity analog
contact point on DAT. Phe320 functions as a gating residue on the outer margin of the S1
binding pocket and performs a crucial role in the transition between the “outward” to
“outward-occluded” states by aromatic interaction with Tyr156 (107). Figure 23 showed
the best RTI 82 docked complex. The phenyl azido moiety interacts with Phe319
(numbering based upon rDAT). In addition, residues homologous to Val152 (TM3) and
Ser421 (TM8), which have been implicated in high-affinity antagonist binding in SERT
were found as contact points for RTI 82 binding (74, 89). Our data suggest [125I]RTI 82
adduction is near the S1 site and thus, the cocaine pharmacophore most likely lies in the
S1 site. This hypothesis was confirmed by cysteine protection studies as RTI 82 protected
only the residues thought to line the S1 site.
We also showed that the [125I]MFZ 2-24 adduction site is either D79 or L80. D79
is an essential amino acid for DA function as its negative charge coordinates the positive
charge of DA and possibly of cocaine. Mutagenesis of D79 and L80 impact DA binding
and its potency to inhibit CFT binding (43, 68). This data also implies that [125I]MFZ 224 adducts close to the S1 site and thus, the cocaine pharmacophore lies in the S1 site.
[125I]RTI 82 and [125I]MFZ 2-24 labeling of DAT occurs with appropriate
pharmacology (100, 101), and because our photolabeling analyses utilized 5 nM ligand,

	
  

84

Figure 23: Computational docking of RTI 82. Best rDAT/RTI 82 docked complex
based on energy and constraint fulfillment. The image depicts transmembrane domains
1, 3, 6 and 8 from the LeuT-based rDAT homology model from the crystal structure of
the “outward occluded” template 2A65. RTI 82 is represented by yellow sticks and
side chains of select residues are represented as lines. Dashed yellow lines indicate
ligand-residue interactions between (1) azido nitrogen of RTI 82 and Phe319, (2)
tropane N of RTI 82 and carboxyl oxygen of Asp79 and (3) phenyl chloride of RTI 82
and side chain N of Asn157.

	
  

85

1 F319

TM3

Y156

TM6
L80

2

N157

3

D79

S421

TM1
TM8

Provided	
  by	
  the	
  Henry	
  Lab,	
  UND.	
  

	
  

86

the [125I]RTI 82 and [125I]MFZ 2-24 attachment site identified in this study represent the
high-affinity, pharmacologically relevant antagonist-bound state of the transporter. It is
likely that this site closely correlates with the (–)-cocaine binding site, as the compounds
share the N-methyl tropane pharmacophore that drives high affinity cocaine recognition
(132). [125I]RTI 82 differs from cocaine only in the substitution of the 3β benzoyl ester
with a phenylchloride and addition of the 2β ethyl aryliodoazido moiety. [125I]MFZ 2-24
differs from cocaine only in the substitution of the 3β benzoyl ester with a phenylchloride
and addition of the aryliodoazido moiety from the tropane N.
We used our data in conjunction with computational docking molecular modeling
studies with comparative DAT models and protection analyses to directly demonstrate
binding of the tropane pharmacophore, which drives the major component of cocaine
analog binding, in the S1 site (132). These findings further enhance our knowledge about
cocaine-DAT molecular interactions. Based upon modeling data, the cocaine
pharmacophore of [125I]RTI 82 and [125I]MFZ 2-24 overlap in the S1 site.
The third high affinity cocaine analog [125I]JHC 2-48 analyzed also displays
appropriate pharmacology as DAT inhibitors were able to displace its labeling and NET
and SERT specific inhibitors failed to do so. The phenylazido moiety of this analog
possibly adducts to a residue in TM 11 or 12 since Ab C-20 immunoprecipitated a ~ 12
kDa fragment. However, there is a possibility of discrepancy between electrophoretic
mobility shift and the fragment size. If that were the case, then [125I]JHC 2-48 adduction
could occur within TMs 9-10 as well. Thus, at this point we are not able to determine the
domain of [125I]JHC 2-48 adduction. However, we are able to eliminate the first three
TMs as the region of adduction based upon a lack of a photolabeled fragment in N-
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terminal Ab pull down. The contact points provided by CNBr and trypsin peptide
mapping were used to triangulate the orientation of the cocaine pharmacophore via
computational modeling, which demonstrates the cocaine pharmacophores of all the
analogs overlap in the S1 site supporting a competitive mechanism of cocaine (Figure 24).
The direct identification of photoaffinity ligand adduction sites confers major
advantages for computational analyses of ligand poses by dramatically reducing the
conformational space that must be sampled during docking analysis, and by providing
experimentally-determined ligand-protein contact points can be used as absolute
requirements by which recovered binding poses can be filtered. This significantly
enhances the confidence with which poses can be interpreted and further analyzed by
computational and mutational strategies to clarify overall transport and transport
inhibition mechanisms. In addition, these procedures can be performed in functional
mammalian transporters in which the WT form is directly compared to transport- and
binding-competent mutant forms, which strongly increases the likelihood that
physiologically relevant structures are being assessed. These multiple strengths support
the utilization of this approach in further predictive docking analyses of these and other
categories of DAT ligands. This is important because to date no SLC6 transporters have
been co-crystalized with cocaine-like compounds or atypical DAT inhibitors, and
because the uncertain structural and functional relationships between mammalian
transporters and the mutation-stabilized dDAT and LeuT/SERT hybrid homologs may
obscure significant differences in the transport and inhibitor binding properties of the
proteins (107, 122). The tremendous sociological and economical impacts of cocaine
addiction make basic understanding the mechanisms of cocaine binding and transport an
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Figure 24: Computational docking of [125I]RTI 82, [125I]MFZ 2-24, and [125I]JHC
2-48.[125I]RTI 82 is depicted in yellow, [125I]MFZ 2-24 is depicted in black and
[125I]JHC 2-48 is depicted in pink. The azido moieties of these analogs are depicted in
purple. The cocaine pharmacophore of these analogs overlap in the S1 pocket as
represented by the blue circle.

	
  

89

125I-MFZ

2-24

125I-RTI

125I-JHC

2-48

Provided by the Henry Lab, UND

	
  

90

82

important effort, especially with the promise afforded by the identification of the
benztropine class of DAT antagonists, which bind to DAT and block DA uptake but do
not produce the cocaine-like behavioral profiles and reduce cocaine self-administration in
animal models (133, 134). It has been suggested that the benztropines may bind distinct
conformations of DAT and/or possess a slow rate of occupancy following administration
which may modulate the psychotropic effects of increased synaptic DA (43, 93, 133, 134).
Identification of cocaine binding residues would be valuable for rational design of
novel agents that can selectively inhibit cocaine binding as antagonists, without (or with
little) effect on the dopamine uptake. Cocaine binds to DAT and stabilizes the transporter
in an open to out confirmation thereby preventing DA translocation. Benztropine is
predicted to stabilize DAT in outward open occulted confirmation. In addition, although
benztropine is predicted to bind in the S1 site and thus, overlap with the DA binding site,
residues involved in benztropine binding are non-identical to residues involved in DA or
CFT binding (43, 93, 114). Different conformations of DAT stabilized by various
inhibitors could be further explored to understand DAT-inhibitor relation in regards to
reinforcing effects.
In this study, we also analyzed novel PALs generated based upon MPH and
bupropion scaffold. MPH is a typical DAT blocker while bupropion is an atypical DAT
blocker. Our preliminary photoaffinity studies showed these novel PALs adduct to DAT
with pharmacological specificity. This opens the possibility of utilizing these PALs for
peptide mapping in order to identify their adduction sites.
Recently, modafinil and its R-enantiomer (Armodafinil) have also been described
as having distinctive interactions at DAT that might contribute to their non-addictive and
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therapeutic profiles (116, 135–137). Thus, understanding cocaine binding in relation to
compounds like these atypical DAT inhibitors could provide critical insights for
developing medication strategies toward treating cocaine addiction. Furthermore, the
synergistic approach of photoaffinity labeling and computational modeling described
here provides a benchmark that validates the use of these methods to investigate the
binding sites for typical and atypical NSS inhibitors.
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APPENDIX

Site-directed Mutagenesis Primers (hDAT)
The primers used for site-directed mutagenesis by the QuikChange® method are shown
below.

	
  

NAME
L70M
Sense
Antisense

SEQUENCE
5’- GGGCAAGAAGATCGACTTTATGCTGTCCGTCATTGGCTT-3’
5’-AAAGCCCAATGACGGACAGCATAAAGTCGATCTTCTTGCCC-3’

F76M
Sense
Antisense

5’-CTGTCCGTCATTGGCATGGCTGTGGACCTGGCC-3’
5’-GGCCAGGTCCACAGCCATGCCAATGACGGACAG -3’

V73M
Sense
Antisense

5’-ATCGACTTTCTCCTGTCCATGATTGGCTTTGCTGTGGAC-3’
5’-GTCCACAGCAAAGCCAATCATGGACAGGAGAAAGTCGAT-3’

V318M
Sense
Antisense

5’-GCGGCCACCCAGATGTGCTTCTCCC-3’
5’-GGGAGAAGCACATCTGGGTGGCCGC-3’

I330M
Sense
Antisense

5’-GTTCGGGGTGCTGATGGCCTTCTCCAG-3’
5’-CTGGAGAAGGCCATCAGCACCCCGAAC-3’

M272L
Sense
Antisense

5’-GGATCACAGCCACCTTGCCATACGTGGT-3’
5’-ACCACGTATGGCAAGGTGGCTGTGATCC-3’

C319M
Sense
Antisense

5’-GCGGCCACCCAGGTGATGTTCTCCCTGGGCGTG-3’
5’-CACGCCCAGGGAGAACATCACCTGGGTGGCCGC-3’

F320M
Sense
Antisense

5’-CACCCAGGTGTGCATGTCCCTGGGCGTGG-3’
5’-CCACGCCCAGGGACATGCACACCTGGGTG-3’
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L322M
Sense
Antisense

5’-GGTGTGCTTCTCCATGGGCGTGGGGTT-3’
5’-AACCCCACGCCCATGGAGAAGCACACC-3’

V324M
Sense
Antisense

5’-TTCTCCCTGGGCATGGGGTTCGGGG-3’
5’-CCCCGAACCCCATGCCCAGGGAGAA-3’

G325M
Sense
Antisense

5’-CTCCCTGGGCGTGATGTTCGGGGTGCTG-3’
5’-CAGCACCCCGAACATCACGCCCAGGGAG-3’

F326M
Sense
Antisense

5’-CCTGGGCGTGGGGATGGGGGTGCTGATCG-3’
5’-CGATCAGCACCCCCATCCCCACGCCCAGG-3’

V328M
Sense
Antisense

5’-CGTGGGGTTCGGGATGCTGATCGCCTT-3’
5’-AAGGCGATCAGCATCCCGAACCCCACG-3’

L329M
Sense
Antisense

5’-GGGGTTCGGGGTGATGATCGCCTTCTC-3’
5’-GAGAAGGCGATCATCACCCCGAACCCC-3’

D79M
Sense
Antisense

5’-TCATTGGCTTTGCTGTGATGCTGGCCAACGTCTGGCG-3’
5’-CGCCAGACGTTGGCCAGCATCACAGCAAAGCCAATGA-3’

S321M
Sense
Antisense

5’-ACCCAGGTGTGCTTCATGCTGGGCGTGGGGTTC-3’
5’-GAACCCCACGCCCAGCATGAAGCACACCTGGGT-3’

M371L
Sense
Antisense

5’-GTGCTTCTGTGCCAAGTACCCCAGGAAGG-3’
5’-CCTTCCTGGGGTACTTGGCACAGAAGCAC-3’
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Site-directed Mutagenesis Primers (rDAT)
The primers used for site-directed mutagenesis by the QuikChange® method are shown
below.
NAME
F76M
Sense
Antisense
V73M
Sense
Antisense

5’-CTATCAGTCATCGGCATGGCTGTGGACCTGGCC-3’
5’-GGCCAGGTCCACAGCCATGCCGATGACTGATAG-3’
5’-CAAGAAAATTGATTTCCTGCTATCAATGATCGGCTTTGCTGTGGA-3’
5’-TCCACAGCAAAGCCGATCATTGATAGCAGGAAATCAATTTTCTTG3’

L70M
Sense
Antisense

5’-GGAGCAAGAAAATTGATTTCATGCTATCAGTCATCGGC-3’
5’-GCCGATGACTGATAGCATGAAATCAATTTTCTTGCTCC-3’

I74M
Sense
Antisense

5’-ATTTCCTGCTATCAGTCATGGGCTTTGCTGTGGA-3’
5’-TCCACAGCAAAGCCCATGACTGATAGCAGGAAAT-3’

G75M
Sense
Antisense

5’-GATTTCCTGCTATCAGTCATCATGTTTGCTGTGGACCTGGCCAAT-3’
5’-ATTGGCCAGGTCCACAGCAAACATGATGACTGATAGCAGGAAATC3’

A77M
Sense
Antisense

5’-CTGCTATCAGTCATCGGCTTTATGGTGGACCTGGCCAATGTCT-3’
5’-AGACATTGGCCAGGTCCACCATAAAGCCGATGACTGATAGCAG-3’

V78M
Sense
Antisense

5’-CTATCAGTCATCGGCTTTGCTATGGACCTGGCC-3’
5’-GGCCAGGTCCATAGCAAAGCCGATGACTGATAG-3’

L80M
Sense
Antisense

5’-GGCTTTGCTGTGGACATGGCCAATGTCTGGA-3’
5’-TCCAGACATTGGCCATGTCCACAGCAAAGCC-3’

M570L
Sense
Antisense

5’-CACATCCTCCATGGCCTTGGTGCCCATTTATGC-3’
5’-GCATAAATGGGCACCAAGGCCATGGAGGATGTG-3’

M568L
Sense
Antisense
M568L/

	
  

SEQUENCE

5’-CGCCACATCCTCCTTGGCCATGGTGCC-3’
5’-GGCACCATGGCCAAGGAGGATGTGGCG-3’
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M570L
Sense
Antisense

5’-CGCCACATCCTCCTTGGCCTTGGTGCCCATTTA-3’
5’-TAAATGGGCACCAAGGCCAAGGAGGATGTGGCG-3’

A569M
Sense
Antisense

5’-CATCGCCACATCCTCCATGATGATGGTGCCCATTTATGCGA-3’
5’-TCGCATAAATGGGCACCATCATCATGGAGGATGTGGCGATG-3’

M11L
Sense
Antisense

5’-ATGCTCCGTGGGACCATTGTCTTCAGTGGTG-3’
5’-CACCACTGAAGACAATGGTCCCACGGAGCAT-3’

M510L
Sense
Antisense

5’-TTCAGTGATGACATCAAGCAATTGACAGGGCAGC-3’
5’-GCTGCCCTGTCAATTGCTTGATGTCATCACTGAA-3’
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